Does Rallies show 13F holders for PDSB?

Yes. Rallies tracks hedge fund and 13F ownership data for PDSB, including fund names, share counts, latest tracked quarter, and position changes when available.

Is PDSB research on Rallies investment advice?

No. Rallies provides research, data, and educational context for PDSB. It does not provide personalized investment advice.

PDSB (PDS Biotechnology Corporation Common Stock) Stock Analysis - Hedge Fund Holdings

PDS Biotechnology Corporation Common Stock (PDSB) is a publicly traded Healthcare sector company. As of May 21, 2026, PDSB trades at $1.06 with a market cap of $65.86M and a P/E ratio of -1.43. PDSB moved +3.50% today. Year to date, PDSB is +20.71%; over the trailing twelve months it is -36.81%. Its 52-week range spans $0.51 to $4.29. Analyst consensus is strong buy with an average price target of $7.50. Rallies surfaces PDSB's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns PDSB stock?

Hedge funds tracked by Rallies that own PDSB include Citadel Advisors, Renaissance Technologies, and Two Sigma. The latest tracked quarter is Dec 31, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for PDS Biotechnology Corporation Common Stock.

PDSB Key Metrics

Key financial metrics for PDSB
Metric	Value
Price	$1.06
Market Cap	$65.86M
P/E Ratio	-1.43
EPS	$-0.74
Dividend Yield	0.00%
52-Week High	$4.29
52-Week Low	$0.51
Volume	734
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-34.50M
Gross Margin	0.00%

Top Hedge Funds Holding PDSB

Citadel Advisors holds 220.22K shares of PDSB, changed +91.52% as of Dec 31, 2024.
Renaissance Technologies holds 100.00K shares of PDSB, changed +331.03% as of Dec 31, 2024.
Two Sigma holds 65.73K shares of PDSB, changed +273.48% as of Dec 31, 2024.

Latest PDSB News

PDS Biotechnology Extends Cash Runway to Q3 2027, Advances PDS0101 to Phase 2 — May 14, 2026
PDS Biotechnology Targets H2 2026 Phase 2 Trial Starts, Extends Cash Runway — May 13, 2026
PDS Biotechnology Narrows Q1 Loss to $7.3M, Amends Phase 3 PFS Endpoint — May 13, 2026
PDS Biotechnology Ends Q4 With $26.7M Cash, Amends VERSATILE-003 Trial Timeline — Mar 31, 2026

Recent PDSB Insider Trades

Freitag Gregory Gene bought 15.06K (~$25.00K) on Feb 28, 2025.
Glover Stephen C. bought 15.06K (~$25.00K) on Feb 28, 2025.

PDSB Analyst Consensus

3 analysts cover PDSB: 0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $7.50.

Common questions about PDSB

Who owns PDSB stock?: Hedge funds tracked by Rallies that own PDSB include Citadel Advisors, Renaissance Technologies, and Two Sigma. The latest tracked quarter is Dec 31, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for PDS Biotechnology Corporation Common Stock.
Does Rallies show 13F holders for PDSB?: Yes. Rallies tracks hedge fund and 13F ownership data for PDSB, including fund names, share counts, latest tracked quarter, and position changes when available.
Is PDSB research on Rallies investment advice?: No. Rallies provides research, data, and educational context for PDSB. It does not provide personalized investment advice.